plerixafor has been researched along with Leucocythaemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Brancaccio, D; Carotenuto, A; D'Alterio, C; Di Leva, FS; Di Maro, S; Ieranò, C; La Pietra, V; Marinelli, L; Napolitano, M; Novellino, E; Portella, L; Scala, S; Sementa, D; Siciliano, RA; Tomassi, S; Trotta, AM | 1 |
| Kato, J; Kikuchi, T; Koda, Y; Mori, T; Okamoto, S; Saburi, M; Sakurai, M; Shigematsu, N; Yamazaki, R | 1 |
| Willyard, C | 1 |
| Choi, J; Cross, SJ; Dallas, MH; Hartford, C; Jacobsen, J; Kang, G; Leung, W; Panetta, JC; Pillai, A; Shook, DR; Srinivasan, A; Sunkara, A; Triplett, BM | 1 |
| Kong, P; Li, J; Ma, Y; Shen, Z; Zeng, D; Zhang, C; Zhang, X; Zhu, L; Zou, Z | 1 |
| Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, C; Zhang, X | 1 |
| Guo, Q; Guo, S; Jin, X; Tang, Y; Tian, C; Xia, B; Zhang, Y; Zhi, Y | 1 |
| Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, X | 1 |
| Argiropoulos, B; Ganser, A; Heuser, M; Humphries, RK; Kuchenbauer, F; Leung, M; Sekulovic, S; Stasiak, M | 1 |
| Jantunen, E | 1 |
| Corona-Rivera, A; Ho, AD; Hoang, VT; Saffrich, R; Sánchez-Enríquez, S; Wagner, W; Walenda, T; Wuchter, P; Zepeda-Moreno, A | 1 |
| O'Doherty, U; Stadtmauer, EA; Tanhehco, YC; Vogl, DT | 1 |
| Fruehauf, S; Seggewiss, R | 1 |
4 review(s) available for plerixafor and Leucocythaemia
| Article | Year |
|---|---|
Are there any new insights for G-CSF and/or AMD3100 in chemotherapy of haematological malignants?
Topics: Antineoplastic Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia; Stem Cell Niche | 2015 |
Novel strategies for blood stem cell mobilization: special focus on plerixafor.
Topics: Animals; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia; Lymphoma; Multiple Myeloma; Stem Cell Transplantation | 2011 |
The evolving role of plerixafor in hematopoietic progenitor cell mobilization.
Topics: Benzylamines; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia; Transplantation, Autologous; Transplantation, Homologous | 2013 |
It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected].
Topics: Adult; Age Factors; Animals; Antineoplastic Agents, Alkylating; Benzylamines; Cell Count; Child; Cyclams; Cyclophosphamide; Cytokines; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia; Leukocyte Count; Male; Mice; Middle Aged; Models, Animal; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Sex Factors; Treatment Outcome | 2003 |
2 trial(s) available for plerixafor and Leucocythaemia
| Article | Year |
|---|---|
Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Transplantation Conditioning; Whole-Body Irradiation | 2021 |
Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Topics: Benzylamines; Biomarkers, Pharmacological; Cyclams; Female; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia; Male; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2014 |
7 other study(ies) available for plerixafor and Leucocythaemia
| Article | Year |
|---|---|
Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.
Topics: Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Colonic Neoplasms; Humans; Leukemia; Models, Molecular; Peptides, Cyclic; Phosphorylation; Receptors, CXCR4 | 2016 |
Stem cells: bad seeds.
Topics: Animals; Benzylamines; Biomarkers, Tumor; Cell Division; Chemokine CXCL12; Cyclams; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Mice; Models, Biological; Neoplastic Stem Cells; Proto-Oncogene Proteins c-hck | 2013 |
[Effects of SDF-1/CXCR4 signal pathway blockade by AMD3100 on the adhesion of leukemia cells to osteoblast niche and the drug resistance of leukemia cells].
Topics: Apoptosis; Benzylamines; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Drug Resistance; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia; Mesenchymal Stem Cells; Osteoblasts; Receptors, CXCR4; Signal Transduction | 2015 |
[Role of CXCR4/STAT3 in mesenchymal stromal cell-mediated drug resistance of acute leukemia cells].
Topics: Acute Disease; Apoptosis; Benzylamines; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Leukemic; Heterocyclic Compounds; Humans; Leukemia; Mesenchymal Stem Cells; Receptors, CXCR4; Signal Transduction; STAT3 Transcription Factor; U937 Cells; Up-Regulation | 2016 |
AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Biomimetic Materials; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Cytarabine; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Polystyrenes; Receptor Cross-Talk; Receptors, CXCR4; Stromal Cells | 2016 |
Priming reloaded?
Topics: Animals; Antineoplastic Agents; Benzylamines; Bone Marrow Transplantation; Cell Movement; Cyclams; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Mice; Neoadjuvant Therapy; Neoplastic Stem Cells; Receptors, CXCR4; Transplantation Conditioning | 2009 |
Modeling SDF-1-induced mobilization in leukemia cell lines.
Topics: Benzylamines; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; Humans; Leukemia; Models, Biological; Receptors, CXCR4 | 2012 |